ClearNote Health

Our Novartis collaborator, Connie Wong, gave a fantastic talk covering our work in PanNET at the recent 14th World CB & CDx Boston Summit. Thank you to everyone who attended the talk or who connected with our team at the event. To learn more about how ClearNote Health is empowering drug development through epigenomics, visit our website: https://lnkd.in/d7aGzQAV #WorldCDx2024 #drugdevelopment #therapyresponse #epigenomics

📢 Our team is at the 14th World CB & CDx Boston Summit! It’s been fantastic connecting with current partners and meeting so many potential new collaborators. Find us at #booth35 and learn more about the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Plus, make sure not to miss the talk from our collaborator, Novartis: Presenter: Connie Wong, Director – Global Biomarker Diagnostics, Novartis Title: Leveraging Novel Liquid Biopsy Technology to Accelerate Translational Research: Circulating Free DNA 5-hydroxymethylcytosine Profiling in Patients with Pancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTA-TATE When: Thursday, Sept 5, 2:50 pm, Track B #WorldCDx2024 #drugdevelopment #therapyresponse #epigenomics

⭐ New Publication Alert!   We’re excited that our latest research, titled “Analytical Validation of an Early Detection Pancreatic Cancer Test using 5-Hydroxymethylation Signatures,” has been published in the The Journal of Molecular Diagnostics.   Following the foundational work by Haan et al. (2023), this publication showcases the rigorous analytical validation of the Avantect Pancreatic Cancer Test. It details key performance metrics, including: > precision > stability > limit of detection (LOD) and compares Avantect to other methylation-based approaches.   This article underscores Avantect’s reliability and accuracy and adds to the growing evidence that Avantect meets the high-quality standards required for clinical testing.   👉 Read the full publication here: https://lnkd.in/dQpz5nhe 🖥 Alternatively, visit our website to learn about the wide range of published research that supports our innovative, #epigenomics based technology: https://lnkd.in/dcadUKsH   #ClearNoteHealth #PancreaticCancer #EarlyDetection

📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit from September 3rd to 6th. 📍 Find us at #Booth35 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Virtuoso empowers more efficient and effective drug development by providing insights into disease biology, therapy response, and resistance - all from a simple blood draw. Reach out to schedule a meeting in advance! #CDx #drugdevelopment #therapyresponse

ClearNote Health is proud to announce the participation of our CEO, Dave Mullarkey, in the Future of Cancer Screening panel at the UBS Genomic Medicine Summit in Dana Point, CA. Dave was joined on the panel by the CEOs of Guardant Health (Amir Ali Talasaz), Exai Bio (Dave Daly), and Delfi (Susan Tousi). The panel was moderated by Dan Leonard, Managing Director for Life Science Tools at UBS US Equity Research. #cancerdiagnostics #clearnotehealth

📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit from September 3rd to 6th. 📍 Find us at #Booth27 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Virtuoso empowers more efficient and effective drug development by providing insights into disease biology, therapy response, and resistance - all from a simple blood draw.    Reach out to schedule a meeting in advance! #CDx #drugdevelopment #therapyresponse

📢 We are pleased to announce that the American Medical Association CPT® has issued ClearNote Health our second Proprietary Laboratory Analysis code, the newest being issued for the Avantect Ovarian Cancer Test. The Avantect Ovarian Cancer test is intended for use in women with suspicion of ovarian cancer, including patients at high risk for the disease, such as women with a genetic predisposition to ovarian cancer as defined by NCCN guidelines, a family history of ovarian cancer or personal history of breast cancer.    According to the ACS, only 20% of ovarian cancers are found early stage, and when found early, the 5-year post-diagnosis survival rate jumps to 94%. New technology will change the way we detect and diagnose cancer in high-risk patients, such as those with a genetic predisposition or family history of cancer. Our dedication to early detection and enabling longer, healthier lives is shared by many in the oncology community. It will take all of us to make a difference in mortality rates.

Don't miss our team at the American Diabetes Association's 84th Scientific Sessions, taking place in Orlando, FL, June 21-24! #pancreaticcancer #ADAscisessions #diabetes

Visit our booth (30149) this weekend at #ASCO24 to learn about our partnership with ClearNote Health. Through our agreement, we will distribute ClearNote’s Virtuoso platform, a blood-based epigenomics platform, to complement our pharmaceutical service offerings. Virtuoso complements our ImmunoID NeXT® and NeXT Personal® tissue and blood-based product portfolio by: - Identifying patients more likely to benefit from the drug treatment - Allowing for non-invasive longitudinal monitoring of patients’ drug response - Providing dynamic insights into therapy response and resistance — all through a simple blood draw Discover more about our partnership here: https://bit.ly/495d2Do. #PrecisionOncology #Genomics #Epigenomics

❓ What do you consider is the main challenge in drug development and translational research? 🎓 Take part in our survey below and let us know!   ClearNote Health is dedicated to optimising drug development and discovery with our Virtuoso epigenomic platform that measures active disease biology to provide dynamic insights into therapy response and resistance - all through a simple blood draw. Attending #ASCO? Contact us at ASCO2024@clearnotehealth.com to set up a time to meet in person at the event. #drugdevelopment #drugdiscovery